{"status":"success","data":{"title":"Influenza - to treat or not to treat?","slug":"influenza-treatment","tags":["Amantadine","Rimantidine","Oseltamivir","Zanamivir"],"collection":["Infectious Disease"],"content":"<h1 id=\"influenza-to-treat-or-not-to-treat-\">Influenza: To treat or not to treat?</h1>\n<ul>\n<li>After the 2009 H1N1 pandemic, the predominant seasonal influenza A strain is H1N1</li>\n</ul>\n<h2 id=\"antiviral-agents\">Antiviral Agents</h2>\n<p>Adamantanes class: <strong><span class=\"drug\">Amantadine</span></strong>, <strong><span class=\"drug\">Rimantidine</span></strong></p>\n<ul>\n<li>Active only against influenza A</li>\n</ul>\n<p>Neuroaminidase inhibitors class: <strong><span class=\"drug\">Oseltamivir</span></strong> (Tamiflu), <strong><span class=\"drug\">Zanamivir</span></strong> (Relenza) </p>\n<ul>\n<li>Active against influenza A and B </li>\n</ul>\n<h2 id=\"influenza-patients-at-high-risk-for-complications-e-g-bacterial-pneumonia-\">Influenza patients at high risk for complications (e.g. bacterial pneumonia)</h2>\n<ul>\n<li>Age &lt; 5 years old (especially &lt; 2 years)</li>\n<li>Age ≤ 18 years old on long-term aspirin</li>\n<li>Age ≥ 65 years old</li>\n<li>American Indian or Alaska Native ethnicity</li>\n<li><p>Comorbidities</p>\n<ul>\n<li>Chronic pulmonary disease</li>\n<li>Cardiovascular disease (excluding hypertension)</li>\n<li>Renal, hepatic, hematologic, metabolic disorders (including DM)</li>\n<li>Neurologic and neurodevelopment conditions (including seizures)</li>\n</ul>\n</li>\n<li><p>Immunosuppressed (HIV or on immunosuppressive medications)</p>\n</li>\n<li>Morbid obesity (BMI ≥ 40 kg/m2)</li>\n<li>Pregnancy or within 2 weeks postpartum</li>\n<li>Residents of nursing homes or chronic-care facilities </li>\n</ul>\n<h2 id=\"cdc-recommendations\">CDC Recommendations</h2>\n<ol>\n<li>Observational study with &gt;700 patients admitted with influenza showed that oseltamivir reduced mortality (hazard ratio=0.27) and earlier hospital discharge (hazard ratio=1.28).</li>\n<li>Give antiviral treatment ASAP for outpatients with confirmed or suspected influenza who are at high risk for complications (see list above). Use clinical judgement.</li>\n<li><strong><span class=\"drug\">Oseltamivir</span></strong> may be used for treatment or chemoprophylaxis for infants &lt;1 year old.</li>\n<li>Consider giving antiviral treatment for confirmed or suspected influenza WITHOUT risk factors for severe illness, if treatment can be started ≤ 48 hours of illness onset. Can reduce duration of uncomplicated influenza A and B illness by 1 day.</li>\n<li>Clinicians should monitor local antiviral resistance surveillance data because resistance patterns may change over time.</li>\n</ol>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm\">Centers for Disease Control &amp; Prevention. Antiviral agents for the tx and chemoprophylaxis of influenza—rec’s of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2011;60:1-24.</a></li>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=21871233\">Dugas AF, Rothman RE. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Ann Emerg Med. 2011;58(3):303-4.</a></li>\n</ul>\n"}}